醒脑静联合纳洛酮治疗肝性脑病患者认知和血清炎症因子水平变化*

doi:10.3969/j.issn.1672-5069.2018.03.043

Abstract

Wang Jun, Zhang Liu, Xiong Huagang, et al. Efficacy of Xingnaojing,a herbal compound,combined with naloxone in treatment of patients with hepatitis B-induced liver cirrhosis complicated by hepatic encephalopathy[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 471-472.

References

[1] 邓磊,李依. 醒脑静联合纳洛酮对肝性脑病患者相关指标的影响. 中国药房,2017,28(12):1630-1632.
[2] Pillitteri CA,Craig LE.Hepatic encephalopathy associated with Hepatitis C lipidosis in Lama glama. Veter Pathol,2013,50(1):177-181.
[3] 张绪清. 肝性脑病的预防与治疗进展.实用肝脏病杂志,2014,19(2):121-124.
[4] 郝艳爽,马普红,曹建国,等. 乙型肝炎肝衰竭患者并发肝性脑病危险因素分析. 实用肝脏病杂志,2016,20(1):90-91,92.
[5] Zheng G,Zhang LJ,Zhong J,et al.Cerebral blood flow measured by arterial-spin labeling MRI:A useful biomarker for characterization of minimal hepatic encephalopathy in patients with cirrhosis. Eur J Radiol,2013,82(11):1981-1988.
[6] 陈爱男,张志明,祝兆林,等. 醒脑静联合纳洛酮对脑出血意识障碍患者的促醒作用. 中国中西医结合急救杂志,2016,23(6):649-650.
[7] 火雷鸣. 醒脑静对脑出血患者脑损害的保护作用.中国老年学杂志,2015,35(2):514-515.
[8] Chen HJ,Zhu XQ,Shu H,et al.Structural and functional cerebral impairments in cirrhotic patients with a history of overt hepatic encephalopathy. Eur J Radiol,2012,81(10):2463-2469.
[9] Merli M,Giusto M,Lucidi C,et al.Muscle depletion increase the risk of overt and minimal hepatic encephalopathy:Results of a prospective study. Metab Brain Dis,2013,28(2):281-284.
[10] 赵宝宁,杨丽艳.醒脑静注射液联合护理干预治疗肝性脑病80例. 中国药业,2015,24(10):115-116,117.
[11] 江文明. 醒脑静治疗肝性脑病35例疗效观察.医学综述,2011,17(24):3828-3829.
[12] 刘自东,刘忠桃.联合纳洛酮综合治疗51例肝性脑病的疗效观察.安徽医学,2010,38(8):965-967.
[13] 罗骞,涂星,熊芬,等. 醒脑静注射液联合纳洛酮治疗急性酒精中毒的经济学分析. 西北药学杂志,2015,30(6):747-750.
[14] Qi R,Zhang LJ,Zhong J,et al.Disrupted thalamic resting-state functional connectivity in patients with minimal hepatic encephalopathy. Eur J Radiol,2013,82(5):850-856.

[1]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[2]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[3]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[4]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[5]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[6]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[7]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[8]	Feng Wenguang, Jiang Wei, Song Guojun.. PPV-guided fluid therapy in patients with hepatolithiasis underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(6): 912-915.
[9]	Li Qiuxi, Jia Jianfeng, Huang Rui.. Clinical value of segmental pedicle hepatectomy and B-ultrasound-guided hepatectomy in the treatment of patients with hepatolithiasis [J]. Journal of Practical Hepatology, 2019, 22(6): 916-919.
[10]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[11]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[12]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[13]	Zhang Xu Lei, Yang Qingyu, Han Qiuyu, et al. Short-term efficacy of herbal medicine in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(5): 660-663.
[14]	Song Haiyan, Chen Xi, Zhang Junfei, et al. Application of vorionazole in the treatment of patients with liver failure complicated by pulmonary fungal infection [J]. Journal of Practical Hepatology, 2019, 22(5): 676-679.
[15]	Dan Zhuyongji, Liu Zhilan, Lu Yanyan, et al. Efficacy of endoscopic sequential variceal 1igation plus sclerotherapy in treatment of patients with hepatitis B-induced liver cirrhosis complicated by esophageal gastric varices bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 692-695.

Efficacy of Xingnaojing,a herbal compound,combined with naloxone in treatment of patients with hepatitis B-induced liver cirrhosis complicated by hepatic encephalopathy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments